Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.
Another histology independent treatment, entrectinib (made by Roche), which NICE is also appraising could become the first histology independent treatment to be available to patients, provided it receives its marketing authorisation.
NICE will be able to say more on this following a preliminary decision on its European licence.
